Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO
2002
Darbepoetin alfa is more effective and requires less frequent dosing than rHuEPO
Sample size: 1185
publication
Evidence: high
Author Information
Author(s): Egrie J, Browne J
Primary Institution: Amgen Inc.
Hypothesis
Darbepoetin alfa (NESP) is more potent than rHuEPO and can be administered less frequently.
Conclusion
Darbepoetin alfa is significantly more potent than rHuEPO, allowing for less frequent dosing in patients.
Supporting Evidence
- Darbepoetin alfa was found to be 3.6-fold more potent than rHuEPO when administered three times per week.
- In a crossover clinical study, 97% of patients maintained on NESP were successfully managed with less frequent dosing.
- Clinical studies confirmed that NESP's longer serum half-life allows for less frequent dosing compared to rHuEPO.
Takeaway
Darbepoetin alfa works better than rHuEPO, so you don't have to take it as often.
Methodology
The study involved comparative pharmacodynamic studies in a normal mouse model and clinical studies in dialysis patients.
Potential Biases
No evidence of antibody formation was found in clinical trials involving over 10,000 patients.
Limitations
Findings from animal models may not directly apply to humans.
Participant Demographics
Patients included those with chronic renal failure and cancer-related anemia.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website